Biorez closed a US $1.5MM funding and affirmed plans for 2019 launch of human clinical studies with a scaffold that may eliminate the need to harvest a patient's tendon for ACL reconstruction.
CellRight Technologies signed a long-term, multi-year distribution agreement with Arthrex for CellRight's orthobiologic products for use in orthopaedic, spine and foot/ankle procedures.
Studies show that use of pulsed electromagnetic field treatment after ACDF significantly increased the fusion rate vs. control at 6 and 12 months, for participants at risk for pseudoarthrosis.